Lv11
50 积分 2025-07-02 加入
Post-HCT maintenance therapy for AML: who, when, why, how long?
3小时前
已完结
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?
3小时前
已完结
The promise of menin inhibitors: from approval to triplet regimens
4小时前
已完结
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?
4小时前
已完结
172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
5天前
已完结
Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
1个月前
已完结
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
1个月前
已完结
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML
2个月前
已完结
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
3个月前
已完结
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
3个月前
已完结
重组人脑利钠肽治疗心力衰竭诱发心肾综合征患者的研究
5个月前
已采纳
皖公网安备34019202002308
